Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360162 | 0.88 | L3MBTL1 (0.45) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL2906606 | 0.85 | L3MBTL1 (0.54) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL1970601 | 0.83 | L3MBTL1 (0.56) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL15071468 | 0.82 | POLB (0.57) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL10039632 | 0.81 | L3MBTL1 (0.54) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL7277285 | 0.81 | L3MBTL1 (0.54) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL4259604 | 0.81 | L3MBTL1 (0.54) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL20117157 | 0.81 | L3MBTL1 (0.54) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL5606459 | 0.81 | ALDH1A1 (0.62) | L3MBTL1POLBLMNARAB9ANPC1 | |
| SCHEMBL3788745 | 0.79 | POLB (0.58) | L3MBTL1POLBLMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0985671-B1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6197768-B1 | THERAPY, PREVENTION ISCHEMIC HEART DISEASE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0985671-A1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-6018046-A | SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |